Expand OGN Menu
OGN MENU

OGN Latest Press Releases

-- January 8, 2026 --

Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo in France, Denmark, Iceland, Sweden, Finland and Norway Business Wire 1:30 AM

-- November 25, 2025 --

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference Business Wire 7:30 AM

-- November 17, 2025 --

Henlius and Organon Announce US FDA Approval of POHERDY (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US Business Wire 5:30 AM

-- November 14, 2025 --

Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN Business Wire 6:37 PM

-- November 10, 2025 --

Organon Reports Results for the Third Quarter Ended September 30, 2025 Business Wire 7:30 AM

-- November 8, 2025 --

New Data Show Early and Consistent Response to VTAMA (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities Business Wire 8:00 AM

-- November 7, 2025 --

Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN PRNewswire 10:47 PM
Organon Announces Agreement to Divest its JADA System for Up to $465 Million to Laborie Business Wire 7:30 AM

-- November 6, 2025 --

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025 Business Wire 7:30 AM

-- October 28, 2025 --

Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN Business Wire 1:04 PM

-- October 27, 2025 --

Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman Globe Newswire 6:22 PM
Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation Business Wire 7:30 AM

-- September 9, 2025 --

Kuehn Law Encourages Investors of Organon & Co. to Contact Law Firm PRNewswire 11:27 AM

-- September 2, 2025 --

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS (denosumab-nxxp) and BILPREVDA (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively Business Wire 5:30 AM

-- August 13, 2025 --

NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation PRNewswire 10:15 AM
Market Data Delayed 15 Minutes